All Stories

Fierce Pharma Asia—AstraZeneca-Alteogen drug delivery deal; Taiho's ADC buyout; WuXi's rosy 2025 outlook

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho is acquiring antibody-drug conjugate expert Araris Biotech. WuXi AppTec expects sales to grow 10% to 15% in 2025. And more.

Mar 21, 2025 - 14:21
 0
Fierce Pharma Asia—AstraZeneca-Alteogen drug delivery deal; Taiho's ADC buyout; WuXi's rosy 2025 outlook
AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho is acquiring antibody-drug conjugate expert Araris Biotech. WuXi AppTec expects sales to grow 10% to 15% in 2025. And more.
Read More

Tags:

Previous Article

Workers say hostile customer interactions more common; want better training

Next Article

Topshop relaunch: what we know so far

Related Posts

Eisai, Biogen's Leqembi emerges from safety reappraisal unscathed as Europe's CHMP endorses slate of new drugs and label expansions

Eisai, Biogen's Leqembi emerges from safety reappraisal...

Feb 28, 2025  0

In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in

In FDA obesity drug battle with compounders, Texas cour...

Mar 6, 2025  0

Novartis plots 427 layoffs in New Jersey as looming Entresto patent cliff sparks marketing refresh

Novartis plots 427 layoffs in New Jersey as looming Ent...

Mar 18, 2025  0